Humanigen Inc (fka HGENQ)

[cowtown jay]

All Taran has to do is to offer their shares in exchange for HGEN shares. That will force a buy-in. Other potential catalysts could be some kind of business relationship, such as a product licensor, with Novavax and/or Sanofi, or regulatory approval, perhaps from Australia, for CMML. The Liquidating Trustee still retains the authority to establish an Existing Equity Interests Record Date, should there be a Distribution to Holders of Allowed Existing Equity Interests. See the footnotes on pp 44 and 45/85.

https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1089767&projectCode=HUM&docketNumber=309&source=DM

Lenz may yet prove to be the biggest blockbuster drug in history, surpassing Humira's $21B earned in 2022. Big Pharma discounted Humanigen's success, because they underestimated our management, and, thanks to the designed-to-fail ACTIV-5 NIAID/NIH trial, they may have also underestimated lenzilumab's safety and efficacy.

It may have been necessary to take this CH11 this far, because Sanofi may not spinoff their healthcare division until Q4, or Q1 of next year.

SG44, please advise if I need to re-evaluate, if you would, please.